Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years

Documenti analoghi

• Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab
  di: Baraliakos, X, et al.
  Pubblicazione: (2005)
• Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
  di: Baraliakos, X, et al.
  Pubblicazione: (2005)
• Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab
  di: Baraliakos, X, et al.
  Pubblicazione: (2005)
• Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
  di: Baraliakos, Xenofon, et al.
  Pubblicazione: (2005)
• Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis
  di: Baraliakos, X, et al.
  Pubblicazione: (2005)